Hepatic Cell News 2.00 January 5, 2018 | |
| |
TOP STORYThe Deubiquitinating Enzyme Cylindromatosis Mitigates Nonalcoholic Steatohepatitis Scientists identified the deubiquitinase cylindromatosis (CYLD) as a suppressor of nonalcoholic steatohepatitis (NASH) in mice and in monkeys. They observed that overexpression of Cyld in hepatocytes concomitantly inhibited lipid accumulation, insulin resistance, inflammation and fibrosis in mice with NASH induced in an experimental setting. [Nat Med] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems The authors investigated the infection and replication of primary isolates of hepatitis E virus in hepatocyte-like cells derived from human embryonic and induced pluripotent stem cells. [Gastroenterology] Abstract Adult Hepatocytes Direct Liver Organogenesis through Non-Parenchymal Cell Recruitment in the Kidney Researchers demonstrated that hepatocytes alone spurred liver organogenesis to form an organ-sized complex 3D liver that exhibited native liver architecture and functions in the kidneys of mice. [J Hepatol] Abstract | Graphical Abstract The authors found that heat shock protein 90 (HSP90) could bind to pyruvate kinase M2 (PKM2) and subsequently increase PKM2 abundance in hepatocellular carcinoma (HCC) cells. In vivo experiments disclosed that PKM2 was required for the promoting effects of HSP90 on the growth of HCC cells in mice. [Mol Cancer] Full Article Hippo Pathway Coactivators Yap and Taz Are Required to Coordinate Mammalian Liver Regeneration Scientists examined the role of Yap and Taz, key components of the Hippo pathway in liver organ size regulation, both in the context of development and homeostasis. Their studies revealed that contrary to the current paradigms that Yap/Taz are not required for developmental regulation of liver size, but are required for proper liver regeneration. [Exp Mol Med] Full Article Investigators studied the effect of activin-A on mouse primary Kupffer cells and hepatic stellate cells and the levels of activin-A and its inhibitor follistatin in the serum of patients from a large panel of liver diseases. [Biochim Biophys Acta] Abstract A Novel Cell Line Based Orthotopic Xenograft Mouse Model that Recapitulates Human Hepatoblastoma Scientists hypothesized that injection of hepatoblastoma (HB) cell lines into the livers of mice would result in liver tumors that resemble their clinical counterparts. Intrahepatic injection of HB cell lines lead to liver tumors in mice with growth patterns and biologic, histologic, and genetic features similar to human HB tumors. [Sci Rep] Full Article High Mobility Group Box 1 Promotes Sorafenib Resistance in Hepg2 Cells and In Vivo The authors investigated the association between high mobility group box 1 (HMGB1) and sorafenib resistance in hepatocellular carcinoma. The HMGB1 knockdown cells exhibited a significantly higher apoptotic level and lower cell viability than the normal HMGB1 expressing cells following the sorafenib treatment. [BMC Cancer] Full Article Researchers compared hepatocyte differentiation of human embryonic stem cells and in a mouse decellularized liver scaffold with standard in vitro protocol. [PLoS One] Full Article | |
| |
REVIEWSThe authors describe the role of osteopontin (OPN) in inflammatory gastrointestinal and liver diseases, focusing on the association of OPN with apoptosis. OPN changes its association with apoptosis depending on the type of disease and the phase of disease activity, acting as a promoter or a suppressor of inflammation and inflammatory carcinogenesis. [Int J Mol Sci] Full Article Visit our reviews page to see a complete list of reviews in the hepatic cell research field. | |
| |
SCIENCE NEWSEnanta Pharmaceuticals Announces Data Presentations Enanta Pharmaceuticals, Inc. announced that two presentations on EDP-305, Enanta’s FXR agonist for non-alcoholic steatohepatitis and primary biliary cholangitis, will be presented. [Press release from Enanta Pharmaceuticals, Inc. discussing research presented at the 2018 NASH-TAG Conference, Park City] Press Release | |
| |
INDUSTRY NEWSCan-Fite BioPharma Ltd. announced the entry into a collaborative research agreement with Hadassah Medical School. This agreement will support research directed by Rifaat Safadi, M.D. aimed at further elucidating the Namodenoson mechanism of action in experimental models of non-alcoholic steatohepatitis (NASH) which represent the human disease. [Can-Fite BioPharma Ltd.] Press Release Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson Can-Fite BioPharma Ltd. provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma. [Can-Fite BioPharma Ltd.] Press Release Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase I/II Study of ARO-HBV Arrowhead Pharmaceuticals Inc. announced that it filed a regulatory submission to begin a Phase I/II study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus infection. [Arrowhead Pharmaceuticals Inc.] Press Release Spitfire Pharma, Inc. announced that SP-1373, its lead glucagon-like peptide-1 and glucagon receptor dual agonist compound, demonstrated superior outcome measures in liver histopathology and metabolic parameters versus semaglutide and elafibranor in the biopsy-proven, AMLN-diet Gubra NASH mouse model. [Spitfire Pharma, Inc. (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSGermany vs Elsevier: Universities Win Temporary Journal Access after Refusing to Pay Fees The Dutch publishing giant Elsevier has granted uninterrupted access to its paywalled journals for researchers at around 200 German universities and research institutes that had refused to renew their individual subscriptions at the end of 2017. [Nature News] Editorial New NCI Director Expects Big Data to Revolutionize Cancer Research, Care Cancer researchers were nervous about who President Donald Trump would choose to replace Harold Varmus as director of the National Cancer Institute (NCI). But their fears of an unconventional candidate proved unfounded when he tapped Norman “Ned” Sharpless. Sharpless, 51, who was then director of the Lineberger Comprehensive Cancer Center at the University of North Carolina in Chapel Hill. [ScienceInsider] Editorial
| |
EVENTSNEW Annual Meeting of the Israel Stem Cell Society 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Assistant – Pediatric Hepatology and Cell Therapy (University of Louvain) NEW Postdoctoral Fellow – Liver Cancer (University Health Network) Postdoctoral Scholar Position – Cancer & Stem Cell Epigenomics (University of California, Davis) Assistant, Associate or Full Professor – Hepatology (University of California, San Diego) Research Fellow – Hepatitis B Virology (National University of Singapore) Research Scientist – Chronic Fibrotic and Metabolic Diseases (Gilead Sciences Inc.) Faculty Positions – Liver Health and Disease (University of Pittsburgh) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hepatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|